REGN2176-3

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Neovascular Age-Related Macular DegenerationNeovascular Wet Age-related Macular Degeneration (AMD)

Phase 1

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

CompletedNCT02061865

Regeneron PharmaceuticalsNeovascular Wet Age-related Macular Degeneration (AMD)

Start: 2014-02-28End: 2014-12-31Updated: 2015-02-11

Phase 2

Study of Intravitreal REGN2176-3 in Participants With Neovascular (Wet) Age-Related Macular Degeneration (AMD)

TerminatedNCT02418754

Regeneron PharmaceuticalsNeovascular Age-Related Macular Degeneration

Start: 2015-05-05End: 2017-04-03Updated: 2020-10-26